miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8
 Corrigendum in /10.3892/mmr.2021.12312

Liu,Ting; Meng,Jingjing; Zhang,Yu

doi:10.3892/mmr.2020.11392

miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8

Corrigendum in: /10.3892/mmr.2021.12312

Authors:
- Ting Liu
- Jingjing Meng
- Yu Zhang
View Affiliations

Affiliations: Department of Nuclear Medicine, The Affiliated Wuhan Central Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China, Department of Thyroid and Breast Surgery, The Affiliated Wuhan Central Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China, Department of Surgery II, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, P.R. China
Published online on: July 30, 2020 https://doi.org/10.3892/mmr.2020.11392
Pages: 3316-3326
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Medullary thyroid carcinoma (MTC) is a relatively rare subtype of thyroid cancer, accounting for 5‑10% of all cases of thyroid cancer worldwide. Due to the current lack of knowledge regarding the tumorigenesis of MTC, the clinical treatment of MTC remains a challenge. It has been reported that microRNAs (miRNAs) regulate the progression of MTC; however, the regulatory network of miRNAs and the exact underlying mechanisms are not completely understood. In the present study, an miRNA expression profile (GSE40807), consisting of 80 samples, was downloaded and analyzed using Gene Expression Omnibus‑2R to identify differentially expressed miRNAs between MTC and normal samples. miR‑592 expression levels were significantly increased in MTC tissues and cell lines compared with normal tissues and cell lines. Patients with high miR‑592 expression levels exhibited a less favorable prognosis compared with patients with low miR‑592 expression. The results suggested that miR‑592 overexpression promoted TT and MZ‑CRC‑1 cell proliferation in vitro. In addition, miR‑592 negatively regulated cyclin‑dependent kinase 8 (CDK8) via targeted binding in MTC cells. Moreover, co‑transfection of CDK8 overexpression plasmid and miR‑592 mimic reversed miR‑592‑mediated MTC cell proliferation. In conclusion, miR‑592 may serve as an oncogene in MTC by decreasing the expression of CDK8, indicating that the miR‑592/CDK8 axis might serve as a promising therapeutic target for MTC.

View Figures

View References

1	Cabanillas ME, McFadden DG and Durante C: Thyroid cancer. Lancet. 388:3316–2795. 2016. View Article : Google Scholar
2	Kushchayev SV, Kushchayeva YS, Tella SH, Glushko T, Pacak K and Teytelboym OM: Medullary thyroid carcinoma: An update on imaging. J Thyroid Res. 2019:18930472019. View Article : Google Scholar : PubMed/NCBI
3	Hao WJ, Zhang H, Yu Y, Zhao J, Ge ZJ, Ding PX, Sun XX, Liu H, Wen SY and You J: Clinical significance and cost-benefit analysis of serum calcitonin assay in diagnosis and treatment of medullary thyroid carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 54:506–509. 2019.(In Chinese). PubMed/NCBI
4	Kebebew E, Greenspan FS, Clark OH, Woeber KA and Grunwell J: Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 200:890–896. 2005. View Article : Google Scholar : PubMed/NCBI
5	Roman S, Lin R and Sosa JA: Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 107:2134–2142. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW and Livhits MJ: Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg. 153:52–59. 2018. View Article : Google Scholar : PubMed/NCBI
7	Ceolin L, Duval M, Benini AF, Ferreira CV and Maia AL: Medullary thyroid carcinoma beyond surgery: Advances, challenges, and perspectives. Endocr Relat Cancer. 26:R499–R518. 2019. View Article : Google Scholar : PubMed/NCBI
8	Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA and Smit JWA: Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: A structured meta-analysis. Clin Endocrinol (Oxf). 72:534–542. 2010. View Article : Google Scholar : PubMed/NCBI
9	Zhang Y, Zhong Q, Chen X, Fang J and Huang Z: Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples. Tumour Biol. 35:9343–9353. 2014. View Article : Google Scholar : PubMed/NCBI
10	Nishino M: Molecular cytopathology for thyroid nodules: A review of methodology and test performance. Cancer Cytopathol. 124:14–27. 2016. View Article : Google Scholar : PubMed/NCBI
11	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
12	Liu X, Jiao Z, Chen H and Wang L: A correlational study on miR-34s and cervical lesions. Eur J Gynaecol Oncol. 39:786–789. 2018.
13	Lu TX and Rothenberg ME: MicroRNA. J Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
14	Tian T, Wang J and Zhou X: A review: microRNA detection methods. Org Biomol Chem. 13:2226–2238. 2015. View Article : Google Scholar : PubMed/NCBI
15	Catalanotto C, Cogoni C and Zardo G: microRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci. 17:17122016. View Article : Google Scholar
16	Yeh M, Oh CS, Yoo JY, Kaur B and Lee TJ: Pivotal role of microRNA-138 in human cancers. Am J Cancer Res. 9:1118–1126. 2019.PubMed/NCBI
17	Humphries B, Wang Z and Yang C: microRNA regulation of epigenetic modifiers in breast cancer. Cancers (Basel). 11:8972019. View Article : Google Scholar
18	Chu YH, Hardin H, Schneider DF, Chen H and Lloyd RV: microRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma. Exp Mol Pathol. 103:229–236. 2017. View Article : Google Scholar : PubMed/NCBI
19	Hou W, Zhang H, Bai X, Liu X, Yu Y, Song L and Du Y: Suppressive role of miR-592 in breast cancer by repressing TGF-β2. Oncol Rep. 38:3447–3454. 2017.PubMed/NCBI
20	Slattery ML, Mullany LE, Sakoda LC, Wolff RK, Samowitz WS and Herrick JS: Dysregulated genes and miRNAs in the apoptosis pathway in colorectal cancer patients. Apoptosis. 23:237–250. 2018. View Article : Google Scholar : PubMed/NCBI
21	Xu Y, Li K, Wang SB and Yang SG: Mir-592 functions as a tumor suppressor in acute myeloid leukemia by targeting ROCK1 and predicts patients' prognosis. Eur Rev Med Pharmacol Sci. 23:1610–1619. 2019.PubMed/NCBI
22	Gao S, Chen J, Wang Y, Zhong Y, Dai Q, Wang Q and Tu J: MiR-592 suppresses the development of glioma by regulating rho-associated protein kinase. Neuroreport. 29:1391–1399. 2018. View Article : Google Scholar : PubMed/NCBI
23	Clough E and Barrett T: The gene expression omnibus database. Methods Mol Biol. 1418:93–110. 2016. View Article : Google Scholar : PubMed/NCBI
24	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
25	The Gene Ontology Consortium, . The gene ontology resource: 20 years and still going strong. Nucleic Acids Res. 47:D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
26	Nikiforova M N, Tseng G C, Steward D, et al: MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility. Journal of Clinical Endocrinology & Metabolism. 93:1600–1608. 2008. View Article : Google Scholar
27	Kanehisa M, Sato Y, Furumichi M, Morishima K and Tanabe M: New approach for understanding genome variations in KEGG. Nucleic Acids Res. 47:D590–D595. 2019. View Article : Google Scholar : PubMed/NCBI
28	Kanehisa M: Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28:1947–1951. 2019. View Article : Google Scholar : PubMed/NCBI
29	Besso MJ, Rosso M, Lapyckyj L, Moiola CP, Matos ML, Mercogliano MF, Schillaci R, Reventos J, Colas E, Gil-Moreno A, et al: FXYD5/dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: Its relationship with TGF-β1 and NF-κB pathways. Front Oncol. 9:13062019. View Article : Google Scholar : PubMed/NCBI
30	Cari L, Nocentini G, Migliorati G and Riccardi C: Potential effect of tumor-specific treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis. Oncoimmunology. 7:e13877052018. View Article : Google Scholar : PubMed/NCBI
31	Li C, Zhou D, Jiang X, Liu M, Tang H and Mei Z: Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker. Gene. 698:9–18. 2019. View Article : Google Scholar : PubMed/NCBI
32	Zhu G, Xie L and Miller D: Expression of microRNAs in thyroid carcinoma. Methods Mol Biol. 1617:261–280. 2017. View Article : Google Scholar : PubMed/NCBI
33	Orlandella FM, Mariniello RM, Iervolino PLC, Imperlini E, Mandola A, Verde A, De Stefano AE, Pane K, Franzese M, Esposito S, et al: miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA. Endocrine. 65:582–594. 2019. View Article : Google Scholar : PubMed/NCBI
34	Zhao P, Ma W, Hu Z, Zhang Y, Zhang S and Wang Y: Up-regulation of miR-340-5p promotes progression of thyroid cancer by inhibiting BMP4. J Endocrinol Invest. 41:1165–1172. 2018. View Article : Google Scholar : PubMed/NCBI
35	Liu X, Fu Y, Zhang G, Zhang D, Liang N, Li F, Li C, Sui C, Jiang J, Lu H, et al: Mir-424-5p promotes anoikis resistance and lung metastasis by inactivating hippo signaling in thyroid cancer. Mol Ther Oncolytics. 15:248–260. 2019. View Article : Google Scholar : PubMed/NCBI
36	Zhang W, Ji W and Zhao X: Mir-155 promotes anaplastic thyroid cancer progression by directly targeting socs1. BMC Cancer. 19:10932019. View Article : Google Scholar : PubMed/NCBI
37	Gong Y, Wu W, Zou X, Liu F, Wei T and Zhu J: Mir-26a inhibits thyroid cancer cell proliferation by targeting arpp19. Am J Cancer Res. 8:1030–1039. 2018.PubMed/NCBI
38	Han J, Zhang M, Nie C, Jia J, Wang F, Yu J, Bi W, Liu B, Sheng R, He G, et al: Mir-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1. Cell Death Dis. 10:1952019. View Article : Google Scholar : PubMed/NCBI
39	Liu H, Deng H, Zhao Y, Li C and Liang Y: Lncrna xist/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through met-Pi3K-Akt signaling. J Exp Clin Cancer Res. 37:2792018. View Article : Google Scholar : PubMed/NCBI
40	Wang P, Gu J, Wang K, Shang J and Wang W: miR-206 inhibits thyroid cancer proliferation and invasion by targeting RAP1B. J Cell Biochem. 120:18927–18936. 2019. View Article : Google Scholar : PubMed/NCBI
41	Saiselet M, Pita JM, Augenlicht A, Dom G, Tarabichi M, Fimereli D, Dumont JE, Detours V and Maenhaut C: miRNA expression and function in thyroid carcinomas: A comparative and critical analysis and a model for other cancers. Oncotarget. 7:52475–52492. 2016. View Article : Google Scholar : PubMed/NCBI
42	Chu YH and Lloyd RV: Medullary thyroid carcinoma: Recent advances including microRNA expression. Endocr Pathol. 27:312–324. 2016. View Article : Google Scholar : PubMed/NCBI
43	Abraham D, Jackson N, Gundara JS, Zhao JT, Gill AJ, Delbridge L, Robinson BG and Sidhu SB: microRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res. 17:4772–4781. 2011. View Article : Google Scholar : PubMed/NCBI
44	Hudson J, Duncavage E, Tamburrino A, Salerno P, Xi L, Raffeld M, Moley J and Chernock RD: Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol. 95:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
45	Yerukala Sathipati S and Ho SY: Identifying a miRNA signature for predicting the stage of breast cancer. Sci Rep. 8:161382018. View Article : Google Scholar : PubMed/NCBI
46	Liu M, Zhi Q, Wang W, Zhang Q, Fang T and Ma Q: Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Biomed Pharmacother. 69:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
47	Fu Q, Du Y, Yang C, Zhang D, Zhang N, Liu X, Cho WC and Yang Y: An oncogenic role of miR-592 in tumorigenesis of human colorectal cancer by targeting forkhead box o3a (FoxO3A). Expert Opin Ther Targets. 20:771–782. 2016. View Article : Google Scholar : PubMed/NCBI
48	Lv Z, Rao P and Li W: MiR-592 represses FOXO3 expression and promotes the proliferation of prostate cancer cells. Int J Clin Exp Med. 8:15246–15257. 2015.PubMed/NCBI
49	He Y, Ge Y, Jiang M, Zhou J, Luo D, Fan H, Shi L, Lin L and Yang L: MiR-592 promotes gastric cancer proliferation, migration, and invasion through the Pi3K/Akt and MAPK/ERK signaling pathways by targeting spry2. Cell Physiol Biochem. 47:1465–1481. 2018. View Article : Google Scholar : PubMed/NCBI
50	Bragelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, et al: Pan-cancer analysis of the mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer. Clin Cancer Res. 23:1829–1840. 2017. View Article : Google Scholar : PubMed/NCBI
51	McDermott MS, Chumanevich AA, Lim CU, Liang J, Chen M, Altilia S, Oliver D, Rae JM, Shtutman M, Kiaris H, et al: Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 8:12558–12575. 2017. View Article : Google Scholar : PubMed/NCBI
52	Liang J, Chen M, Broude EV and Roninson IB: Role of transcription-regulating kinase CDK8 in colon cancer metastasis. Oncotarget. 10:622–623. 2019. View Article : Google Scholar : PubMed/NCBI
53	Philip S, Kumarasiri M, Teo T, Yu M and Wang S: Cyclin-dependent kinase 8: A new hope in targeted cancer therapy? J Med Chem. 61:5073–5092. 2018. View Article : Google Scholar : PubMed/NCBI
54	Crown J: CDK8: A new breast cancer target. Oncotarget. 8:14269–14270. 2017. View Article : Google Scholar : PubMed/NCBI
55	Song W, Wu S, Wu Q, Zhou L, Yu L, Zhu B and Gong X: The microRNA-141-3p/CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab. J Cell Biochem. 120:14095–14106. 2019. View Article : Google Scholar : PubMed/NCBI
56	Wei R, Kong L, Xiao Y, Yuan H, Song Y, Wang J, Yu H, Mao S and Xu W: CDK8 regulates the angiogenesis of pancreatic cancer cells in part via the CDK8-β-catenin-klf2 signal axis. Exp Cell Res. 369:304–315. 2018. View Article : Google Scholar : PubMed/NCBI
57	Xing S, Xu Q, Fan X, Wu S and Tian F: Downregulation of miR-138-5p promotes non-small cell lung cancer progression by regulating CDK8. Mol Med Rep. 20:5272–5278. 2019.PubMed/NCBI